Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program

Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the best small-cap biotech stocks to buy according to analysts.

On November 11, 2025, Jones Trading’s Soumit Roy reiterated his “Buy” rating on Janux Therapeutics, Inc. (NASDAQ:JANX), which reflects promising developments in the company’s prostate cancer program. The analyst highlighted the company’s mature data from its Phase 1 trials, which is expected to be released in the fourth quarter of 2025. This includes the company’s innovative T cell-engaging therapies, JANX007 and JANX008. Both therapies have seen significant progress in the prostate cancer space, with JANX007 being tested in earlier metastatic castration-resistant prostate cancer (mCRPC) settings. The total addressable market for these treatments is estimated at $10 billion in the U.S. alone.

Soumit Roy also highlighted the improved efficacy and durability of responses in the taxane-naïve setting, as shown through the promising preliminary data from JANX007. The analyst’s confidence was also boosted by Janux Therapeutics, Inc.’s (NASDAQ:JANX) healthy cash balance of $989 million as of the end of the third quarter.

Janux Therapeutics, Inc. (NASDAQ:JANX) reported its Q3 results on November 7, 2025, recording a net loss of $24.3 million, an improvement from $28.1 million in Q3 2024. The quarter marked strong momentum in its Phase 1 trials for its lead candidates, including T cell-engaging therapies, with preliminary data indicating enhanced efficacy and durability of responses. The company demonstrated disciplined cost management during the quarter, recording a reduction in general and administrative expenses despite an increase of $34.6 million in ongoing R&D investment.

Janux Therapeutics, Inc. (NASDAQ:JANX), a clinical-stage biopharmaceutical company, develops novel immunotherapies using its proprietary TRACTr and ARM platforms.

While we acknowledge the potential of JANX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential.

Disclosure: None.